Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial

In the REGONIVO study, regorafenib combined with nivolumab was effective in the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC), which indicated anti-angiogenic drugs may enhance the efficacy of immune checkpoint inhibitors. Therefore, we designed a single-arm, single-ce...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Cancer Res
Hlavní autoři: Ren, Chao, Mai, Zong-Jiong, Jin, Ying, He, Ming-Ming, Wang, Zhi-Qiang, Luo, Hui-Yan, Zhang, Dong-Sheng, Wu, Chen-Yi, Wang, Feng, Xu, Rui-Hua
Médium: Artigo
Jazyk:Inglês
Vydáno: e-Century Publishing Corporation 2020
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539766/
https://ncbi.nlm.nih.gov/pubmed/33042628
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky